Alaunos Therapeutics (TCRT) Common Equity (2009 - 2026)
Alaunos Therapeutics' (TCRT) quarterly Common Equity came in at $1.3 million in Q1 2026, up 21.74% YoY from $1.1 million in Q1 2025, and down 40.18% on a QoQ basis from $2.2 million in Q4 2025.
Alaunos Therapeutics (TCRT) Common Equity (2009 - 2026) Analysis & Trends
Alaunos Therapeutics (TCRT) has 18 years of Common Equity data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Common Equity rose 21.74% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 21.74% YoY) and the FY2025 annual result came in at $2.2 million, up 4.36% from the prior year.
- Common Equity declined to $1.3 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $49.1 million in Q1 2022 to a low of $1.1 million in Q1 2025.
- A 5-year average of $15.0 million and a median of $4.8 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity plunged 83.74% — and 2026, when it advanced 21.74%.
- Tracing TCRT's Common Equity over 5 years: stood at $38.6 million in 2022, then sank by 83.64% to $6.3 million in 2023, then plunged by 67.29% to $2.1 million in 2024, then advanced by 4.36% to $2.2 million in 2025, then plunged by 40.18% to $1.3 million in 2026.
- The last three Common Equity figures came in at $1.3 million (Q1 2026), $2.2 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Alaunos Therapeutics | 4.28 Mn | 4.16 Mn | - | 652,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.29 Mn |
| Dec 31, 2025 | 2.15 Mn |
| Sep 30, 2025 | 2.80 Mn |
| Jun 30, 2025 | 3.66 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Sep 30, 2024 | 2.72 Mn |
| Jun 30, 2024 | 3.77 Mn |
| Mar 31, 2024 | 4.80 Mn |
| Dec 31, 2023 | 6.31 Mn |
| Sep 30, 2023 | 13.90 Mn |
| Jun 30, 2023 | 21.65 Mn |
| Mar 31, 2023 | 29.51 Mn |
| Dec 31, 2022 | 38.56 Mn |
| Sep 30, 2022 | 32.11 Mn |
| Jun 30, 2022 | 40.18 Mn |
| Mar 31, 2022 | 49.12 Mn |
| Dec 31, 2021 | 58.06 Mn |
| Sep 30, 2021 | 68.71 Mn |
| Jun 30, 2021 | 88.28 Mn |